Arimoclomol Receives the Fast Track Designation for the Treatment of ALS
source: pixabay.com

Arimoclomol Receives the Fast Track Designation for the Treatment of ALS

CytRx Corporation has recently received the Fast Track designation for their ALS treatment, arimoclomol. This status was also given for the treatment of Niemann-Pick disease and sporadic Inclusion Body Myositis…

Continue Reading Arimoclomol Receives the Fast Track Designation for the Treatment of ALS

Sanofi is Making Strides in Lysosomal Storage Disease Research

Sanofi There are an estimated 350 million rare disease patients across the world. Many conditions still don't have treatments. However, there are scientists dedicating their lives solely to this endeavor.…

Continue Reading Sanofi is Making Strides in Lysosomal Storage Disease Research
A Primer on Clinical Trials for Patients With Gaucher Disease and Other Rare Illnesses
mcmurryjulie / Pixabay

A Primer on Clinical Trials for Patients With Gaucher Disease and Other Rare Illnesses

According to a post from gaucherdisease.org, clinical trials are an essential component to the development and testing of new therapies for Gaucher disease and other rare diseases. For some rare…

Continue Reading A Primer on Clinical Trials for Patients With Gaucher Disease and Other Rare Illnesses
India Turns to Enzyme Replacement Therapy as it Seeks to Address Rare Diseases
klbz / Pixabay

India Turns to Enzyme Replacement Therapy as it Seeks to Address Rare Diseases

According to a story from health.economictimes.indiatimes.com, the country of India is currently beginning to take more steps in order to address the dire unmet medical need of its rare disease…

Continue Reading India Turns to Enzyme Replacement Therapy as it Seeks to Address Rare Diseases
Takeda Pharmaceutical Launches Trio of Enzyme Replacement Therapies in India to Treat Lysosomal Storage Disorders
source: pixabay.com

Takeda Pharmaceutical Launches Trio of Enzyme Replacement Therapies in India to Treat Lysosomal Storage Disorders

According to a press release from Takeda Pharmaceutical Company published by For Press Release, the Company has launched a collection of enzyme replacement therapies for use in the treatment of…

Continue Reading Takeda Pharmaceutical Launches Trio of Enzyme Replacement Therapies in India to Treat Lysosomal Storage Disorders

Gaucher Disease Patient and Activist Successfully Improves the Care for Other Rare Disease Patients in Her Country

This is the story of a brave journalist who was determined to improve care for rare disease patients in her country, North Macedonia. North Macedonia is a developing country located…

Continue Reading Gaucher Disease Patient and Activist Successfully Improves the Care for Other Rare Disease Patients in Her Country

Recent Study Indicates Lyso-Gb1 is an Extremely Effective Biomarker for Monitoring Children with Gaucher Disease

Gaucher disease (GD) is a rare lysosomal storage disorder. It is caused by a deficiency in the glucocerebrosidase enzyme. In June, a new study was published in the International Journal of…

Continue Reading Recent Study Indicates Lyso-Gb1 is an Extremely Effective Biomarker for Monitoring Children with Gaucher Disease

Singapore Launches the Rare Disease Fund to Help Patients Cope with Exorbitant Drug Costs

Rare Disease Fund Many families affected by rare diseases cannot afford the necessary treatments. Due to the small population of people these diseases affect, exorbitant price tags are often placed…

Continue Reading Singapore Launches the Rare Disease Fund to Help Patients Cope with Exorbitant Drug Costs

Rare Diseases: Only 10% of India’s 1.37 Billion People Have Health Insurance

In about five years India’s population will exceed that of China which is currently ranked number one according to population. Contrast these numbers with the fact that only ten percent…

Continue Reading Rare Diseases: Only 10% of India’s 1.37 Billion People Have Health Insurance

Diagnostic Timeline for Lysosomal Storage Disorders like Fabry Disease Significantly Reduced in South Africa

The Problem Lysosomal storage disorders (LSDs) affect approximately one out of every 7,000 people. There are around 50 different types of LSDs. These include Fabry disease, Batten disease, Gaucher disease,…

Continue Reading Diagnostic Timeline for Lysosomal Storage Disorders like Fabry Disease Significantly Reduced in South Africa